Table 4.
Univariable regression models of patients with AHD (n = 126).
| Non-Relapse Mortality | Relapse | RFS | OS | |||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Age at transplantation, years | 1.00 (0.97–1.03) | 0.8 | 1.02 (0.99–1.04) | 0.2 | 1.01 (0.99–1.03) | 0.3 | 1.00 (0.98–1.02) | 0.8 |
| Female gender | 0.57 (0.26–1.23) | 0.2 | 0.80 (0.46–1.41) | 0.4 | 0.71 (0.45–1.12) | 0.14 | 0.66 (0.41–1.07) | 0.089 |
| WBC count at diagnosis, G/L | 1.00 (0.99–1.01) | 0.6 | 1.00 (0.99–1.01) | 0.8 | 1.00 (0.99–1.01) | >0.9 | 1.00 (0.99–1.01) | 0.9 |
| Cytogenetic risk (MRC) | ||||||||
| Favorable | ||||||||
| Intermediate | Ref. | Ref. | Ref. | Ref. | ||||
| Adverse | 0.51 (0.20–1.32) | 0.2 | 1.80 (1.01–3.20) | 0.046 | 1.18 (0.73–1.89) | 0.5 | 1.01 (0.61–1.66) | >0.9 |
| Time from last remission to HCT, days | 1.00 (0.99–1.01) | >0.9 | 1.00 (1.00–1.01) | 0.3 | 1.00 (1.00–1.01) | 0.3 | 1.00 (1.00–1.00) | 0.7 |
| Disease status at HCT | ||||||||
| First remission | Ref. | Ref. | Ref. | Ref. | ||||
| Second remission | 1.12 (0.39–3.22) | 0.8 | 1.71 (0.86–3.42) | 0.13 | 1.49 (0.84–2.65) | 0.2 | 1.23 (0.68–2.24) | 0.5 |
| MFC MRD status before HCT | ||||||||
| MRD-negative | Ref. | Ref. | Ref. | Ref. | ||||
| MRD-positive | 1.08 (0.52–2.25) | 0.8 | 2.21 (1.28–3.81) | 0.005 | 1.70 (1.10–2.61) | 0.016 | 1.75 (1.12–2.72) | 0.014 |
| Recovered peripheral blood counts before HCT | 0.91 (0.46–1.82) | 0.8 | 1.26 (0.72–2.20) | 0.4 | 1.11 (0.72–1.71) | 0.6 | 1.10 (0.70–1.71) | 0.7 |
| HCT-CI category | ||||||||
| Low | Ref. | Ref. | Ref. | Ref. | ||||
| Intermediate | 1.33 (0.57–3.11) | 0.5 | 1.06 (0.50–2.22) | 0.9 | 1.17 (0.67–2.04) | 0.6 | 1.51 (0.83–2.75) | 0.2 |
| High | 1.85 (0.76–4.49) | 0.2 | 2.51 (1.27–4.94) | 0.008 | 2.26 (1.32–3.86) | 0.003 | 2.58 (1.45–4.58) | 0.001 |
| Stem cell source | ||||||||
| BM | Ref. | Ref. | Ref. | Ref. | ||||
| PBSC | 0.21 (0.06–0.71) | 0.012 | 1.54 (0.21–11.2) | 0.7 | 0.54 (0.20–1.48) | 0.2 | 0.38 (0.14–1.06) | 0.066 |
| Cord blood | 0.52 (0.11–2.34) | 0.4 | 2.68 (0.32–22.3) | 0.4 | 1.07 (0.33–3.41) | >0.9 | 0.70 (0.21–2.29) | 0.6 |
| HLA matching | ||||||||
| Identical related donor | Ref. | Ref. | Ref. | Ref. | ||||
| Matched unrelated donor | 1.12 (0.47–2.68) | 0.8 | 1.70 (0.78–3.72) | 0.2 | 1.43 (0.80–2.54) | 0.2 | 1.14 (0.64–2.05) | 0.7 |
| 1–2 allele mismatch | 1.28 (0.42–3.95) | 0.7 | 1.57 (0.57–4.33) | 0.4 | 1.42 (0.67–3.02) | 0.4 | 1.36 (0.63–2.93) | 0.4 |
| Haplo-identical | 6.03 (0.69–52.5) | 0.10 | 5.39 (1.11–26.1) | 0.036 | 5.35 (1.51–19) | 0.009 | 4.33 (1.24–15.1) | 0.022 |
| Cord blood | 2.56 (0.75–8.74) | 0.13 | 2.73 (0.94–7.90) | 0.064 | 2.61 (1.17–5.81) | 0.019 | 2.05 (0.90–4.68) | 0.086 |
| Conditioning regimen intensity | ||||||||
| MAC | Ref. | Ref. | Ref. | Ref. | ||||
| Non-MAC | 0.88 (0.44–1.76) | 0.7 | 2.11 (1.18–3.77) | 0.012 | 1.48 (0.96–2.29) | 0.075 | 1.06 (0.68–1.65) | 0.8 |
Abbreviations: BM, bone marrow; ELN, European LeukemiaNet; HCT, hematopoietic cell transplantation; HCT-CI, HCT comorbidity index; HLA, human leukocyte antigen; MAC, myeloablative conditioning; MFC, multiparameter flow cytometry; MRC, U.K. Medical Research Council; MRD, measurable residual disease; PBSC, peripheral blood stem cells; WBC, white blood cell count.